Orforglipron: what it is and what the evidence says
A GLP-1 receptor agonist that is NOT a peptide but a small molecule: that is why it can be taken orally without being degraded in the stomach.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Weight management, type 2 diabetes.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
There is a broad phase 3 program in people. ATTAIN-1, with 3,127 adults with obesity and without diabetes, showed an average weight reduction of 11.1% versus 2.1% with placebo at 72 weeks. ATTAIN-2, in obesity with type 2 diabetes, and ACHIEVE-1, in type 2 diabetes, showed reductions in weight and glycated hemoglobin.
The limitation that matters most
Because the approval is so recent, long-term cardiovascular safety data with this molecule are still lacking, and glucose control is not yet an indication in the prescribing information. Digestive effects are the main reason for stopping.
Regulatory status
Approved by the FDA on April 1, 2026 (Foundayo) for chronic weight management in adults, and reported in the United Kingdom in August 2026. In the European Union and Mexico, its status should be checked with the local agency. It is not listed by name on the WADA 2026 Prohibited List.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Prescription medicine, approved very recently. It demands strict dosing conditions.
With a history of medullary thyroid carcinoma or pancreatitis, pregnancy, breastfeeding, or treatment with insulin or sulfonylureas, the decision belongs to the doctor before starting.
What this page cannot give you
A reference page can take you this far. You know what Orforglipron is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesityhuman N Engl J Med · 2023 · PMID 37351564 →
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyhuman Lancet · 2023 · PMID 37369232 →
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialhuman Lancet · 2026 · PMID 41275875 →
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialhuman Nat Med · 2026 · PMID 42120723 →
- Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials Diabetes Obes Metab · 2026 · PMID 42338042 →
- Orforglipron: First Approvalreview Drugs · 2026 · PMID 42479349 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Orforglipron or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Orforglipron?
A GLP-1 receptor agonist that is NOT a peptide but a small molecule: that is why it can be taken orally without being degraded in the stomach. It is studied within the area of metabolic.
Is there human evidence for Orforglipron?
There is a broad phase 3 program in people. ATTAIN-1, with 3,127 adults with obesity and without diabetes, showed an average weight reduction of 11.1% versus 2.1% with placebo at 72 weeks. ATTAIN-2, in obesity with type 2 diabetes, and ACHIEVE-1, in type 2 diabetes, showed reductions in weight and glycated hemoglobin.
Is it approved by any health agency?
Approved by the FDA on April 1, 2026 (Foundayo) for chronic weight management in adults, and reported in the United Kingdom in August 2026. In the European Union and Mexico, its status should be checked with the local agency. It is not listed by name on the WADA 2026 Prohibited List.
What is the dose of Orforglipron?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Orforglipron is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.